The challenge of HLA donor specific antibodies in the management of pancreatic islet transplantation: an illustrative case-series.

Archive ouverte

Maanaoui, Mehdi | Chetboun, Mikael | Top, Isabelle | Elsermans, Vincent | Pattou Kerr-Conte, Julie | Le Mapihan, Kristell | Defrance, Frederique | Gmyr, Valery | Hubert, Thomas | Labalette, Myriam | Hazzan, Marc | Vantyghem, Marie-Christine | Pattou, Francois

Edité par CCSD ; Nature Publishing Group -

International audience. Islet transplantation is a unique paradigm in organ transplantation, since multiple donors are required to achieve complete insulin-independence. Preformed or de novo Donor Specific Antibodies (DSA) may target one or several donor islets, which adds complexity to the analysis of their impact. Adult patients with type 1 diabetes transplanted with pancreatic islets between 2005 and 2018 were included in a single-center observational study. Thirty-two recipients with available sera tested by solid-phase assays for anti-HLA antibodies during their whole follow-up were analyzed. Twenty-five recipients were islet-transplantation-alone recipients, and 7 islet-after-kidney recipients. Seven recipients presented with DSA at any time during follow-up (two with preformed DSA only, one with preformed and de novo DSA, 4 with de novo DSA only). Only islet-transplantation-alone recipients presented with de novo DSA. Three clinical trajectories were identified according to: 1/the presence of preformed DSA, 2/early de novo DSA or 3/late de novo DSA. Only late de novo DSA were associated with unfavorable outcomes, depicted by a decrease of the β-score. Islet transplantation with preformed DSA, even with high MFI values, is associated with favorable outcomes in our experience. On the contrary, de novo DSA, and especially late de novo DSA, may be associated with allograft loss.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion